IRLAB Therapeutics AB Class A Statistics
Want to see SE:IRLAB.A full AI Analyst Report?
IRLAB Therapeutics AB Class A (IRLAB.A) Stock Statistics & Valuation Metrics
Total Valuation
IRLAB Therapeutics AB Class A has a market cap or net worth of SEK 114.36M. The enterprise value is SEK 187.72M.
- Market Cap
- SEK 114.36M
- Enterprise Value
- SEK 187.72M
Share Statistics
IRLAB Therapeutics AB Class A has 148,632,140 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 148,632,140
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
IRLAB Therapeutics AB Class A’s return on equity (ROE) is -3.58 and return on invested capital (ROIC) is -152.21%.
- Return on Equity (ROE)
- -3.58
- Return on Assets (ROA)
- -0.80
- Return on Invested Capital (ROIC)
- -152.21%
- Return on Capital Employed (ROCE)
- -3.01
- Revenue Per Employee
- 1.85M
- Profits Per Employee
- -3.55M
- Employee Count
- 31
- Asset Turnover
- 0.42
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of IRLAB Therapeutics AB Class A is -1.53. IRLAB Therapeutics AB Class A’s PEG ratio is -0.01.
- PE Ratio
- -1.53
- PS Ratio
- 1.70
- PB Ratio
- 1.37
- Price to FCF
- -1.48
- Price to Operating Cash Flow
- -1.42
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, IRLAB Therapeutics AB Class A had revenue of 57.46M and earned -110.01M in profits. Earnings per share was -1.64.
- Revenue
- 57.46M
- Gross Profit
- -92.35M
- Operating Income
- -92.35M
- Pretax Income
- -110.01M
- Net Income
- -110.01M
- EBITDA
- -88.03M
- Earnings Per Share (EPS)
- -1.64
Cash Flow
In the last 12 months, operating cash flow was -77.27M and capital expenditures 0, giving a free cash flow of -77.27M billion.
- Operating Cash Flow
- -77.27M
- Free Cash Flow
- -77.27M
- Free Cash Flow per Share
- -0.54
Dividends & Yields
IRLAB Therapeutics AB Class A pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -67.60%
- Earnings Yield
- -42.63%
Stock Price Statistics
- Beta
- 0.42
- 52-Week Price Change
- -65.22%
- 50-Day Moving Average
- 1.83
- 200-Day Moving Average
- 1.54
- Relative Strength Index (RSI)
- 25.85
- Average Volume (3m)
- 2.79M
Important Dates
IRLAB Therapeutics AB Class A upcoming earnings date is Feb 24, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Feb 24, 2027
- Ex-Dividend Date
- ―
Financial Position
IRLAB Therapeutics AB Class A as a current ratio of 0.80, with Debt / Equity ratio of 97.51%
- Current Ratio
- 0.80
- Quick Ratio
- 0.80
- Debt to Market Cap
- 0.20
- Net Debt to EBITDA
- 0.59
- Interest Coverage Ratio
- -5.13
Taxes
In the past 12 months, IRLAB Therapeutics AB Class A has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
IRLAB Therapeutics AB Class A EV to EBITDA ratio is -1.05, with an EV/FCF ratio of -0.54.
- EV to Sales
- 0.62
- EV to EBITDA
- -1.05
- EV to Free Cash Flow
- -0.54
- EV to Operating Cash Flow
- -0.54
Balance Sheet
IRLAB Therapeutics AB Class A has SEK 90.64M in cash and marketable securities with SEK 17.93M in debt, giving a net cash position of SEK 72.71M billion.
- Cash & Marketable Securities
- SEK 90.64M
- Total Debt
- SEK 17.93M
- Net Cash
- SEK 72.71M
- Net Cash Per Share
- SEK 0.49
- Tangible Book Value Per Share
- SEK 0.23
Margins
Gross margin is -64.85%, with operating margin of -64.85%, and net profit margin of -69.35%.
- Gross Margin
- -64.85%
- Operating Margin
- -64.85%
- Pretax Margin
- -69.35%
- Net Profit Margin
- -69.35%
- EBITDA Margin
- -58.73%
- EBIT Margin
- -64.85%
Analyst Forecast
The average price target for IRLAB Therapeutics AB Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -21.20%
- EPS Growth Forecast
- 68.24%
Scores
- Smart Score
- ―
- AI Score
- 42

